Certolizumab pegol is a tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis. Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).
- Mechanism
- Curator reviewed · 4 references
Certolizumab targets the activation of TNF-alpha with high affinity (KD 90 pM and IC90 0.004 mcg/ml) which inhibits the downstream inflammatory process. It acts by binding and neutralizing the soluble and membrane portions of TNF-alpha without inducing complement or antibody-dependent cytotoxicity due to the lack of the Fc region. The inhibition of TNF-alpha is achieved in a dose-dependent manner and it does not present activity against lymphotoxin alpha (TNF-beta).
One additional feature od certolizumab pegol is that, due to the presence of the PEGylation, it is more significantly distributed into inflamed tissues when compared to other TNF-alpha inhibitors such as infliximab and adalimumab.
- Primary indication
- Certolizumab pegol has been approved for several different conditions listed below: Symptomatic management of Chron's disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to...Curator reviewed · 16 structured indications
- Formula / weight
- C2115H3252N556O673S16 · 91000.0 Da (Pegylated)
- First approval
- Canada, 2009 · United States, 2008 · European Union, 2016
- Code names
- CDP-870 · PHA-738144
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Certolizumab pegol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account